Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells

PLoS Computational Biology

Volumn 6, Issue 12, 2010, Pages

  Panetta, John C ^a,b   Sparreboom, Alex ^a,b   Pui, Ching Hon ^a,b   Relling, Mary V ^a,b   Evans, William E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CYTOLOGY; DISEASES;

ACTIVE METABOLITES; ACUTE LYMPHOBLASTIC LEUKAEMIAS; CELL/B.E; FOLATES; IN-VIVO; LEUKAEMIA CELLS; MODEL MECHANISMS; PHARMACOKINETIC MODELING; POLYGLUTAMATE; SYNTHETASES;

PHARMACOKINETICS;

FOLIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; DRUG DERIVATIVE; POLYGLUTAMIC ACID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CELL LINEAGE; CONTROLLED STUDY; DIPLOIDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION PROFILING; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PURINE SYNTHESIS; SIGNAL TRANSDUCTION; BIOLOGY; BLOOD; CELL DIVISION; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL;

CELL DIVISION; COHORT STUDIES; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLIC ACID; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; METHOTREXATE; POLYGLUTAMIC ACID; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 78651245722     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1001019     Document Type: Article

References (31)

1. Dordelmann M, Reiter A, Zimmermann M, Fengler R, Henze G, et al. (1998) Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 20: 444-450.
2. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, et al. (2001) Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 97: 1211-1218.
3. Chauvenet AR, Martin PL, Devidas M, Linda SB, Bell BA, et al. (2007) Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood 110: 1105-1111.
4. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, et al. (1996) Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 97: 73-80.
5. Kager L, Cheok M, Yang W, Zaza G, Cheng Q, et al. (2005) Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 115: 110-117.
6. Synold TW, Relling MV, Boyett JM, Rivera GK, Sandlund, et al. (1994) Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 94: 1996-2001.
7. Whitehead VM, Rosenblatt DS, Vuchich MJ, Shuster JJ, Witte A, et al. (1990) Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood 76: 44-49.
8. Whitehead VM, Vuchich MJ, Lauer SJ, Mahoney D, Carroll AJ, et al. (1992) Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 80: 1316-1323.
9. Panetta JC, Yanishevski Y, Pui CH, Sandlund JT, Rubnitz J, et al. (2002) A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemother Pharmacol 50: 419-428.
10. Jackson RC, Hart LI, Harrap KR (1976) Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrololate reductases. Cancer Res 36: 1991-1997.
11. Morrison PF, Allegra CJ (1987) The kinetics of methotrexate polyglutamation in human breast cancer cells. Arch Biochem Biophys 254: 597-610.
12. Nijhout HF, Reed MC, Budu P, Ulrich CM (2004) A mathematical model of the folate cycle: new insights into folate homeostasis. J Biol Chem 279: 55008-55016.
13. Reed MC, Nijhout HF, Neuhouser ML, Gregory JF, III, Shane B, et al. (2006) A mathematical model gives insights into nutritional and genetic aspects of folatemediated one-carbon metabolism. J Nutr 136: 2653-2661.
14. Ulrich CM, Neuhouser M, Liu AY, Boynton A, Gregory JF, III, et al. (2008) Mathematical modeling of folate metabolism: predicted effects of genetic polymorphisms on mechanisms and biomarkers relevant to carcinogenesis. Cancer Epidemiol Biomarkers Prev 17: 1822-1831.
15. Nijhout HF, Reed MC, Lam SL, Shane B, Gregory JF, III, et al. (2006) In silico experimentation with a model of hepatic mitochondrial folate metabolism. Theor Biol Med Model 3: 40.
16. Assaraf YG, Ifergan I, Kadry WN, Pinter RY (2006) Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets. J Theor Biol 240: 637-647.
17. Seither RL, Trent DF, Mikulecky DC, Rape TJ, Goldman ID (1989) Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. Experimental and network thermodynamic analyses of the role of dihydrofolate polyglutamylates in antifolate action in cells. J Biol Chem 264: 17016-17023.
18. Seither RL, Trent DF, Mikulecky DC, Rape TJ, Goldman ID (1991) Effect of direct suppression of thymidylate synthase at the 5,10-methylenetetrahydrofolate binding site on the interconversion of tetrahydrofolate cofactors to dihydrofolate by antifolates. Influence of degree of dihydrofolate reductase inhibition. J Biol Chem 266: 4112-4118.
19. French D, Yang W, Cheng C, Raimondi SC, Mullighan CG, et al. (2009) Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood 113: 4512-4520.
20. Belkov VM, Krynetski EY, Schuetz JD, Yanishevski Y, Masson E, et al. (1999) Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood 93: 1643-1650.
21. Barredo JC, Synold TW, Laver J, Relling MV, Pui CH, et al. (1994) Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in Blineage and T-lineage leukemia. Blood 84: 564-569.
22. Galpin AJ, Schuetz JD, Masson E, Yanishevski Y, Synold TW, et al. (1997) Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol 52: 155-163.
23. Rots MG, Pieters R, Peters GJ, Noordhuis P, van Zantwijk CH, et al. (1999) Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood 93: 1677-1683.
24. Dervieux T, Brenner TL, Hon YY, Zhou Y, Hancock ML, et al. (2002) De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood 100: 1240-1247.
25. Winick N, Martin PL, Devidas M, Shuster J, Borowitz MJ, et al. (2007) Delayed Intensification (DI) Enhances Event-Free Survival (EFS) of Children with BPrecursor Acute Lymphoblastic Leukemia (ALL) Who Received Intensification Therapy with Six Courses of Intravenous Methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group Study (COG). ASH Annual Meeting Abstracts 110: 583.
26. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, et al. (2009) Treating childhood acute lymphoblastic leukemia without cranial irradiation. NEngl JMed 360: 2730-2741.
27. D'Argenio DZ, Schumitzky A, Wang X (2009) ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software, version 5. Biomedical Simulations Resource (Los Angeles).
28. Bauer RJ, Guzy S (2004) Monte Carlo Parameter Expectation Maximization (MCPEM) Method for Analyzing Population Pharmacokinetic/Pharmacodynamic Data. In: D'Argenio DZ, ed. Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis. Massachusetts: Kluwer Academic Publishers. pp 155-163.
29. White JC, Mikulecky DC (1981) Application of network thermodynamics to the computer modeling of the pharmacology of anticancer agents: a network model for methotrexate action as a comprehensive example. Pharmac Ther 15: 251-291.
30. Sorich MJ, Pottier N, Pei D, Yang W, Kager L, et al. (2008) In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med 5: e83.
31. Yang JJ, Cheng C, Yang W, Pei D, Cao X, et al. (2009) Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301: 393-403.